# Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

> **NCT02194985** · PHASE3 · COMPLETED · sponsor: **Amicus Therapeutics** · enrollment: 84 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** migalastat HCl 150 mg

## Key facts

- **NCT ID:** NCT02194985
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-14
- **Primary completion:** 2019-10-23
- **Final completion:** 2019-10-23
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194985, "Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02194985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*